– Eight posters presented on Friday and Saturday highlight comprehensive results of TANGO-2, a multi-center, randomized, open label clinical trial of VABOMERE vs. “best available therapy” in subjects with known or suspected CRE –
– VABOMERE was recently approved for the treatment of adult patients with complicated urinary tract infections, including polynephritis, caused by designated susceptible enterobacteriacea –
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products will be featured in presentations at IDWeek 2017 to be held October 4-8, 2017 in San Diego. The Medicines Company’s infectious disease research and product development is focused on the most serious multi-drug resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE).
The Company will present data on VABOMERE™, its recently FDA-approved fixed-dose meropenem-vaborbactam antibiotic combination, from the TANGO-2, the multi-center, randomized, open-label Phase III clinical trial of VABOMERE versus “best available therapy” in patients with serious infections (complicated urinary tract infections (cUTI), bacteremia, hospital-acquired or ventilator-associated bacterial pneumonia, and complicated intraabdominal infections) suspected or documented to be caused by CRE.
Data from studies of the Company’s other marketed products ORBACTIV® (oritavancin) and MINOCIN® (minocycline) for Injection will also be presented.
“We are delighted to have the opportunity at IDWeek, the premier gathering of the infectious disease community, to showcase our industry leading portfolio of anti-infectives, including presentation of key data for VABOMERE which was exquisitely designed to address the growing problem of KPC-producing CRE,” said Michael Dudley, PharmD, FIDSA, Senior Vice President, Head of R&D and Co-Leader of The Medicines Company’s Infectious Disease Business.
